Naotoshi Sugimoto

Leveraging E7386 phase 1 trials for cardiac safety: Gaining concentration-QTc insights to inform early-stage oncology development.

Shriram M. Pathak, Nozomi Hayata, Juanita Lopez, Natalie Cook et autres

e24005 Background: E7386 is a novel oral anticancer agent that inhibits the interaction between β-catenin and CREB-binding protein. Phase 1 studies provide an efficient approach to cardiac safety assessment by using data across a range of doses to model the concentration-QTc (C-QTc) …

gb, jp, us (code pays fourni par la source)

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Jin Li, M. Fernández, Felipe Reyes-Cosmelli, Yamilé Peña et autres

PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710 ) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adenocarcinoma. METHODS Eligible participants 18 years and older with untreated human epidermal growth factor receptor 2–negative locally …

cn, jp, de, cl, es, gt, us, co, pl, kr, be, fr (code pays fourni par la source)

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study

Koki Nakanishi, Naotoshi Sugimoto, Yasuhiro Kodera, H. Kawakami et autres

Background: EN-DEAVOR was a multi-institutional retrospective study evaluating the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in gastric cancer patients. This secondary analysis investigated prognostic factors for real-world progression-free survival (rwPFS) and objective response rate (ORR) for T-DXd as third- or later-line …

jp, de, in (code pays fourni par la source)

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda et autres

PURPOSE: Microsatellite instability-high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) …

jp (code pays fourni par la source)

Clinical Use of Comprehensive Genomic Profiling Tests in Intrahepatic Cholangiocarcinoma: A Single‐Center Retrospective Study

Makiko Urabe, Takuo Yamai, Kenji Ikezawa, Kazuhiro Kozumi et autres

ABSTRACT The clinical utility of comprehensive genomic profiling (CGP) in intrahepatic cholangiocarcinoma (ICC) remains to be fully elucidated. This study analysed CGP test results and evaluated treatment outcomes with fibroblast growth factor receptor (FGFR) inhibitors in patients with ICC, aiming to assess …

jp (code pays fourni par la source)

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

Toshifumi Yamaguchi, K Taira, Shinya Tokunaga, Takeshi Kato et autres

BACKGROUND/AIM: The combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety and efficacy of this regimen in Japanese patients have not been sufficiently investigated. PATIENTS AND METHODS: /day (days 1-14) …

jp (code pays fourni par la source)

A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results

Junji Kawada, Daisuke Sakai, Yutaka Kimura, Motohiro Hirao et autres

BACKGROUND/AIM: Irinotecan is a key drug for patients with advanced gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in patients with advanced human epidermal growth factor receptor type 2 (HER2)-positive chemotherapy-refractory gastric cancer. PATIENTS AND …

jp (code pays fourni par la source)

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Naotoshi Sugimoto, Junji Kawada, Yoshio Oka, Kohei Murakami et autres

Background/Aim: No prospective study has evaluated salvage chemotherapy with capecitabine plus oxaliplatin (XELOX) in patients with gastric cancer who are resistant to or intolerant of cisplatin. Patients and Methods: This multicenter, open-label, single-arm, phase II study was conducted at six centers in …

jp (code pays fourni par la source)

Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

Yutaka Kimura, Naotoshi Sugimoto, Shunji Endo, Ryohei Kawabata et autres

jp (code pays fourni par la source)

Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan

Kei Kunimasa, Naotoshi Sugimoto, Tomoyuki Yamasaki, Yoji Kukita et autres

INTRODUCTION: Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real-world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness. METHODS: We analyzed data …

jp (code pays fourni par la source)

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto et autres

Abstract Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor 2-positive (HER2 + ) gastric cancer in the DESTINY-Gastric01 trial. Exploratory results from DESTINY-Gastric01 suggested a potential benefit in patients with HER2-low gastric cancer. Spatial …

jp, kr, us (code pays fourni par la source)

Theobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats

Kentaro Matsuzaki, Naotoshi Sugimoto, Md. Hossain, Rafiad Islam et autres

Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder and dopaminergic dysfunction in the prefrontal cortex (PFC) may play a role.Our previous research indicated that theobromine (TB), a methylxanthine, enhances cognitive function in rodents via the PFC.This study investigates TB's effects on hyperactivity and …

jp, bd, us (code pays fourni par la source)